Oncozenge

Oncozenge EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncozenge (ONCOZ.ST) as of Oct 28, 2026 is -15.87 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -8.69 M SEK — a change of 82.73% (lower).

EBITDA

-15.87 MSEK

YoY

82.73%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncozenge is 2025 -15.87 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncozenge was 2024 -8.69 M SEK. It decreases by 82.73% lower compared to the previous year.

The Oncozenge EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-801,000.00 SEK
Jan 1, 2021
-4.89 M SEK
Jan 1, 2022
-43.57 M SEK
Jan 1, 2023
-15.90 M SEK
Jan 1, 2024
-8.69 M SEK
Jan 1, 2025
-15.87 M SEK
The Oncozenge EBITDA history
YEAREBITDAYoY
-15.87 MSEK+82.73%
-8.69 MSEK-45.38%
-15.90 MSEK-63.50%
-43.57 MSEK+790.25%
-4.89 MSEK+510.99%
-801,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oncozenge Stock analysis

What does Oncozenge do? OncoZenge AB develops BupiZenge, a bupivacaine lozenge formulation targeting oral pain from cancer treatments like radiotherapy and chemotherapy. The company focuses on clinical studies for regulatory approval, aiming to address oral mucositis, a severe complication requiring pain relief. BupiZenge is positioned as a solution for patients needing immediate relief during cancer therapy, with strategic efforts centered on its development and registration. OncoZenge AB targets healthcare providers and oncology centers that treat cancer patients experiencing oral mucositis. The firm's product addresses a specific clinical need, aligning with treatment protocols for cancer care. By developing a dedicated lozenge formulation, OncoZenge AB seeks to secure market access through regulatory pathways, focusing on the unmet demand in cancer pain management. Oncozenge is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncozenge stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncozenge is -15.87 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncozenge changed from -8.69 M SEK to -15.87 M SEK, representing a 82.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Oncozenge since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Oncozenge historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Oncozenge

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Oncozenge